Search Clinical Trials
Thank you for your interest in Vanderbilt research! Taking part in research is one way to be part of tomorrow’s health care discoveries. Vanderbilt is always looking for volunteers just like you so that our researchers can better understand how to prevent, diagnose, and treat diseases. Everyone is needed. Both healthy volunteers and people with health conditions can help us answer important questions that impact the health of our communities. Ready to start searching for a study?
- Enter a health condition or leave it blank if you are looking to join any study as a healthy volunteer.
- Enter your gender and age.
- Click View Results.
- Click on the study titles for information.
- Click on Contact/Details tab to get information for contacting the study team.
Condition of Interest |
---|
Retrieval Practice for Word Learning for Deaf and Hard of Hearing Children
Hearing Loss
Language Impairment
This study is designed to advance the promising yet underutilized research on retrieval
practice by evaluating the effectiveness and efficiency of two key retrieval practice
features (feedback and spacing). The study uses four single case adapted alternating
treatments studies, each with four 5- to... expand
This study is designed to advance the promising yet underutilized research on retrieval practice by evaluating the effectiveness and efficiency of two key retrieval practice features (feedback and spacing). The study uses four single case adapted alternating treatments studies, each with four 5- to 8-year-old children who are deaf and hard of hearing to evaluate the effects of feedback and spacing on the efficiency of word learning and retention. Type: Interventional Start Date: Feb 2023 |
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
Advanced Hematologic Malignancy
Relapsed Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Relapsed Myelodysplastic Syndromes
Refractory Myelodysplastic Syndromes
This Phase 1, multicenter, open-label, dose escalation study is designed to assess the
safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary
clinical activity of FHD-286 administered orally as monotherapy or combination therapy,
in subjects with advanced hematologic malignancies. expand
This Phase 1, multicenter, open-label, dose escalation study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 administered orally as monotherapy or combination therapy, in subjects with advanced hematologic malignancies. Type: Interventional Start Date: Jun 2021 |
Post-market Study of the Biodesign Hernia Graft
Ventral Hernia
The purpose of this study is to collect data on the performance of the Biodesign® Hernia
Graft when used to reinforce soft tissues during ventral hernia repair. expand
The purpose of this study is to collect data on the performance of the Biodesign® Hernia Graft when used to reinforce soft tissues during ventral hernia repair. Type: Observational Start Date: Nov 2020 |
Connect® Myeloid Disease Registry
Primary Myelofibrosis
Myelodysplastic Syndromes
Leukemia, Myeloid, Acute
The purpose of the Connect® Myeloid disease registry is to provide unique insights into
treatment decisions and treatment patterns as they relate to clinical outcomes of
patients with myeloid diseases in routine clinical practice. This disease registry will
also evaluate molecular and cellular markers... expand
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes. Type: Observational [Patient Registry] Start Date: Dec 2013 |
Augmenting Benzodiazepine Receptor Agonist Deprescribing With Acupuncture and Yoga Among Older Adults
Anxiety
Insomnia
Benzodiazepine
Deprescription
The main purpose of this 12-week study is to see if a new combination of treatments can
help older adults reduce benzodiazepine or related medication use. The treatment
combination consists of 1) medical provider visits to gradually reduce the medication
dose over 12 weeks, 2) acupuncture treatments,... expand
The main purpose of this 12-week study is to see if a new combination of treatments can help older adults reduce benzodiazepine or related medication use. The treatment combination consists of 1) medical provider visits to gradually reduce the medication dose over 12 weeks, 2) acupuncture treatments, and 3) private yoga classes. Participants will be offered weekly visits for 12 weeks to receive combined treatments. Participants will be provided surveys before, during, and after the study to learn about their experience of the treatments. At the end of the study, participants will be invited to participate in a focus group to learn about their experience in the study. Type: Interventional Start Date: Dec 2023 |
The PREDICTOR Study: Assessing Diagnostic Predictors of Airway Collapse in Patients With Obstructive...
Sleep Apnea, Obstructive
This study is an exploratory, multicenter study of up to 300 subjects diagnosed with
obstructive sleep apnea who are being evaluated for airway surgery. Subjects will undergo
standard evaluation for airway surgery as part of standard of care. In addition to the
standard airway assessment, a simple,... expand
This study is an exploratory, multicenter study of up to 300 subjects diagnosed with obstructive sleep apnea who are being evaluated for airway surgery. Subjects will undergo standard evaluation for airway surgery as part of standard of care. In addition to the standard airway assessment, a simple, non-invasive measurement of the width of the inside of each subjects mouth will be performed. This measurement takes 2-3 minutes to perform. Type: Interventional Start Date: May 2022 |
Disclosing Dementia Risk Based on Plasma Phosphorylated Tau
Alzheimer Disease
Mild Cognitive Impairment
Novel blood-based biomarkers of Alzheimer's disease (AD), such as plasma levels of tau
phosphorylated at threonine 181 (p-tau181), have shown great promise in detecting early
AD pathology. While current studies point to this biomarker as having great clinical
utility, one necessary step before clinical... expand
Novel blood-based biomarkers of Alzheimer's disease (AD), such as plasma levels of tau phosphorylated at threonine 181 (p-tau181), have shown great promise in detecting early AD pathology. While current studies point to this biomarker as having great clinical utility, one necessary step before clinical implementation is developing safe and effective methods for disclosure of results. Past risk disclosure studies have shown that disclosing risk for AD based on genetics or amyloid status is safe, but these studies have largely focused on cognitively unimpaired individuals. This study seeks to develop comprehensible educational materials to aid risk disclosure and examine the effect of risk disclosure based on plasma p-tau181 results in a group of participants with mild cognitive impairment (MCI) at imminent risk of converting to dementia. First, educational materials will be developed in collaboration with health communication experts and then refined in focus groups made up of individuals with MCI. Educational materials will be analyzed on several key reading and comprehensibility metrics and will include personalized risk estimate based on a well-accepted risk algorithm (Cullen, et al., 2021). Next, these educational materials will be utilized to disclose risk in a randomized controlled trial with an active control arm receiving disclosure based on age, sex, and cognitive status (based on Mini-Mental State Examination), meant to mimic common methods of clinical diagnostic and prognostic decision making, and an intervention arm receiving disclosure based on the above factors plus plasma p-tau181 results. Outcomes will include measures of comprehension and psychological well-being (anxiety, depression, hopelessness, and distress) and will be assessed immediately after risk disclosure and again at six-month follow-up. It is hypothesized that risk disclosure based on plasma p-tau181 is not more psychologically harmful or less comprehensible than disclosure based on demographic factors and MMSE. This pilot study will provide a necessary step towards moving plasma p-tau biomarkers towards safe clinical implementation and will develop educational materials that can be utilized in future studies and clinical practice. Type: Interventional Start Date: Sep 2022 |
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Frontotemporal Lobar Degeneration (FTLD)
Progressive Supranuclear Palsy (PSP)
Corticobasal Degeneration (CBD)
Behavioral Variant Frontotemporal Dementia (bvFTD)
Semantic Variant Primary Progressive Aphasia (svPPA)
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the
formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01
AG045390; funded through 2019) as a single North American research consortium to study
FTLD for 2019 and beyond. expand
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond. Type: Observational Start Date: Mar 2020 |
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
Autonomic Failure
Pure Autonomic Failure
Multiple System Atrophy
Parkinson Disease
Orthostatic Hypotension
The purpose of this study is to learn more about the effects of midodrine and droxidopa,
two medications used for the treatment of orthostatic hypotension (low blood pressure on
standing), on the veins of the abdomen of patients with autonomic failure. The study will
be conducted at Vanderbilt University... expand
The purpose of this study is to learn more about the effects of midodrine and droxidopa, two medications used for the treatment of orthostatic hypotension (low blood pressure on standing), on the veins of the abdomen of patients with autonomic failure. The study will be conducted at Vanderbilt University Medical Center, and consists of 2 parts: a screening and 2 testing days. The total length of the study will be about 5 days. About 34 participants will be screened for the study. Type: Interventional Start Date: Sep 2016 |
The Vanderbilt Atrial Fibrillation Ablation Registry
Atrial Fibrillation
The Vanderbilt Atrial Fibrillation Ablation registry (VAFAR) is a prospective clinical
and genetic biorepository that systematically enrolls patients undergoing atrial
fibrillation (AF) ablation. The registry was started in 2011 and has greater than 1000 AF
ablation records with stored blood and DNA... expand
The Vanderbilt Atrial Fibrillation Ablation registry (VAFAR) is a prospective clinical and genetic biorepository that systematically enrolls patients undergoing atrial fibrillation (AF) ablation. The registry was started in 2011 and has greater than 1000 AF ablation records with stored blood and DNA samples. The goals of VAFAR are to: 1) identify clinical, genetic, and serological predictors of response to AF ablation in order to improve patient selection, and 2) to provide a resource for translational research investigating the electrophysiologic mechanisms of AF pathogenesis. Type: Observational [Patient Registry] Start Date: Oct 2011 |
Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes
Bloodstream Infection
Sepsis Bacterial
MRSA Bacteremia
Vancomycin
Bacterial blood stream infections are common and life-threatening. Bloodstream infections
have historically been identified using blood cultures, which often take 24-72 hours to
result and are imperfectly sensitive. Early administration of antimicrobial therapy is a
fundamental component of the management... expand
Bacterial blood stream infections are common and life-threatening. Bloodstream infections have historically been identified using blood cultures, which often take 24-72 hours to result and are imperfectly sensitive. Early administration of antimicrobial therapy is a fundamental component of the management of adults presenting to the hospital with a suspected bloodstream infection and/or sepsis. But because blood cultures frequently take 24-72 hours to result, patients are typically treated with empiric, broad spectrum antibiotics. In a meta-analysis of sepsis studies, empirical antibiotic therapy was inappropriate for the organism that ultimately grew in culture in almost half of patients. Thus, patients are commonly exposed to unnecessary antibiotics without evidence of infection or with evidence of infection requiring narrow antibiotic selection. For example, current guidelines recommend the use of empiric intravenous vancomycin as coverage for a bloodstream infection caused by the bacterial pathogen methicillin-resistant S. aureus (MRSA). Vancomycin requires careful monitoring due to its narrow therapeutic range and high risk of toxicity. Administration of vancomycin to patients who do not have MRSA can lead to avoidable adverse drug events and costs, as well as drive antimicrobial resistance. There has been increasing interest in using rapid diagnostic tests that identify bacteria directly from whole blood samples without relying on growth in culture, referred to as "direct-from-blood" tests, to guide early therapeutic management of patients with suspected bloodstream infections in addition to standard blood cultures. One such FDA-approved, direct-from-blood test is the T2Bacteria® Panel. This panel's performance as a direct-from blood test for bacterial pathogens has been described in previous studies. A recent meta-analysis of largely observational studies reported a faster transition to targeted microbial therapy and de-escalation of empirical microbial therapy, as well as a shorter duration of intensive care unit stay and hospital stay for patients who received this direct-from-blood test. We will conduct a pragmatic, randomized clinical trial examining the effect of using the T2Bacteria® Panel direct from-blood testing, compared to using blood cultures alone (standard of care), on antimicrobial receipt and clinical outcomes for adults presenting to the hospital with suspected infection and who have been initiated on empiric therapy with intravenous vancomycin. Type: Interventional Start Date: Dec 2023 |
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel...
Metastatic Salivary Gland Carcinoma
Recurrent Salivary Gland Carcinoma
Stage III Major Salivary Gland Cancer AJCC v8
Stage IV Major Salivary Gland Cancer AJCC v8
Unresectable Salivary Gland Carcinoma
This phase II trial tests whether ado-trastuzumab emtansine works to shrink tumors in
patients with HER2-positive salivary gland cancer that has come back (recurrent), spread
to other places in the body (metastatic), or cannot be removed by surgery (unresectable).
Trastuzumab emtansine is a monoclonal... expand
This phase II trial tests whether ado-trastuzumab emtansine works to shrink tumors in patients with HER2-positive salivary gland cancer that has come back (recurrent), spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable). Trastuzumab emtansine is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called emtansine. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers emtansine to kill them. Trastuzumab emtansine may work better compared to usual treatment of chemotherapy with docetaxel and trastuzumab in treating patients with salivary gland cancer. Type: Interventional Start Date: Sep 2022 |
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment...
Prostate Adenocarcinoma
This phase III trial uses the Decipher risk score to guide intensification (for higher
Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to
better match therapies to an individual patient's cancer aggressiveness. The Decipher
risk score evaluates a prostate cancer... expand
This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient's cancer aggressiveness. The Decipher risk score evaluates a prostate cancer tumor for its potential for spreading. In patients with low risk scores, this trial compares radiation therapy alone to the usual treatment of radiation therapy and hormone therapy (androgen deprivation therapy). Radiation therapy uses high energy x-rays or particles to kill tumor cells and shrink tumors. Androgen deprivation therapy blocks the production or interferes with the action of male sex hormones such as testosterone, which plays a role in prostate cancer development. Giving radiation treatment alone may be the same as the usual approach in controlling the cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy. In patients with higher Decipher gene risk, this trial compares the addition of darolutamide to usual treatment radiation therapy and hormone therapy, to usual treatment. Darolutamide blocks the actions of the androgens (e.g. testosterone) in the tumor cells and in the body. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading. Type: Interventional Start Date: Nov 2021 |
2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia...
Familial Hypercholesterolemia
The Investigators will test the hypothesis that 2-HOBA will reduce modification of HDL
and LDL and improve HDL function in humans with heterozygous FH. The Investigators plan
to first study subjects with Familial Hypercholesterolemia (FH), treating them with 750
mg of 2-HOBA or placebo every 8 hours... expand
The Investigators will test the hypothesis that 2-HOBA will reduce modification of HDL and LDL and improve HDL function in humans with heterozygous FH. The Investigators plan to first study subjects with Familial Hypercholesterolemia (FH), treating them with 750 mg of 2-HOBA or placebo every 8 hours for 6 weeks. Type: Interventional Start Date: Feb 2024 |
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
Amblyopia
A randomized trial to determine whether simultaneous treatment with spectacles and
patching has an equivalent VA outcome compared with sequential treatment, first with
spectacles alone followed by patching (if needed), for previously untreated amblyopia in
children 3 to <13 years of age. expand
A randomized trial to determine whether simultaneous treatment with spectacles and patching has an equivalent VA outcome compared with sequential treatment, first with spectacles alone followed by patching (if needed), for previously untreated amblyopia in children 3 to <13 years of age. Type: Interventional Start Date: Dec 2020 |
Clarifying the Optimal Application of SLT Therapy Trial
Glaucoma and Ocular Hypertension
The goal of this study is to understand if SLT performed at low energy is as effective as
SLT performed at standard energy, and also to see if repeating SLT at low energy once a
year will prevent or delay the need for daily eye drop medications better than waiting
for SLT to wear off before repeating... expand
The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it. Type: Interventional Start Date: Sep 2021 |
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease
Von Willebrand Diseases
This is a multi-center, Phase 1a study to assess the safety, tolerability, PK, and PD of
VGA039 following single IV or SC dose administration in healthy subjects and Von
Willebrand disease patients. expand
This is a multi-center, Phase 1a study to assess the safety, tolerability, PK, and PD of VGA039 following single IV or SC dose administration in healthy subjects and Von Willebrand disease patients. Type: Interventional Start Date: Mar 2023 |
A Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic...
Eosinophilic Gastritis
Eosinophilic Duodenitis
Eosinophilic Gastrointestinal Disease
The study is researching an experimental drug called dupilumab. The study is focused on
participants with active eosinophilic gastritis (EoG) with or without eosinophilic
duodenitis (EoD). Participants with EoD only are not eligible for enrollment. EoG and EoD
are uncommon, persistent, allergic/immune... expand
The study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD). Participants with EoD only are not eligible for enrollment. EoG and EoD are uncommon, persistent, allergic/immune diseases in which eosinophils (a type of white blood cell) gather in large numbers in the stomach and small intestine and cause inflammation and damage. The aim of the study is to evaluate the effect of dupilumab on relieving EoG (with or without EoD) symptoms and reducing inflammation in the stomach and, if applicable, small intestine in adults and adolescents aged 12 years and older, compared to placebo. The study is looking at several other research questions, including: - What side effects may happen from taking the study drug - How much study drug is in your blood at different times - Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) Type: Interventional Start Date: May 2023 |
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Immunization; Infection
Transplantation Infection
Influenza
Lung allograft recipients have a higher burden of influenza disease and greater
associated morbidity and mortality compared with healthy controls. Induction and early
maintenance immunosuppression is thought to impair immunogenicity to standard dose
inactivated influenza vaccine. This early post-transplant... expand
Lung allograft recipients have a higher burden of influenza disease and greater associated morbidity and mortality compared with healthy controls. Induction and early maintenance immunosuppression is thought to impair immunogenicity to standard dose inactivated influenza vaccine. This early post-transplant period is when immunity is most desirable, since influenza disease during this time frame is associated with adverse consequences. Thus, strategies to reduce severe influenza disease in this highly susceptible population are critical. No trials in lung transplant recipients have evaluated two doses of HD-IIV within the same influenza season as a strategy to improve immunogenicity and durability of influenza prevention. Furthermore, no influenza vaccine trials have focused on enrollment of subjects at early post-transplant timepoints. Very few studies have been performed in solely lung allograft recipients. Immunosuppression intensity is highest in lung patients, thereby limiting comparisons to recipients of heart, liver, and kidney transplants. Therefore, studies to assess both HD-IIV and two-dose strategies in the same influenza season in post-lung transplant recipients are greatly needed. The central hypothesis of our proposal is that lung allograft recipients who are 1-35 months post-transplant and receiving two doses of HD-quadrivalent inactivated influenza vaccine (QIV) will have higher HAI geometric mean titers (GMT) to influenza antigens compared to those receiving two doses of SD-QIV. To test this hypothesis and address the above critical knowledge gaps, we propose to conduct a phase II, multi-center, randomized, double-blind, controlled immunogenicity and safety trial comparing the administration of two doses of HD-QIV to two doses of SD-QIV in lung allograft recipients 1-35 months post-transplant. The results of this clinical trial will address significant knowledge gaps regarding influenza vaccine strategies (e.g., one vs. two doses and HD-QIV vs. SD-QIV) and immune responses in lung transplant recipients and will guide vaccine recommendations during the post-transplant period. Type: Interventional Start Date: Nov 2022 |
Casting vs Bracing for Idiopathic Early-Onset Scoliosis
Scoliosis Idiopathic
Early-Onset Scoliosis Deformity of Spine
Comparison of casting and bracing for the treatment of idiopathic early onset scoliosis expand
Comparison of casting and bracing for the treatment of idiopathic early onset scoliosis Type: Interventional Start Date: Feb 2021 |
The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral...
Peripheral Arterial Disease
The purpose of this study is to understand how the drug rivaroxaban improves symptoms
associated with peripheral artery disease. expand
The purpose of this study is to understand how the drug rivaroxaban improves symptoms associated with peripheral artery disease. Type: Interventional Start Date: Apr 2022 |
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
MDS/MPN
ABNL-MARRO (A Basket study of Novel therapy for untreated MDS/MPN and Relapsed/Refractory
Overlap Syndromes) is an international European-American cooperation providing the
framework for collaborative studies to advance treatment of
myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and explore... expand
ABNL-MARRO (A Basket study of Novel therapy for untreated MDS/MPN and Relapsed/Refractory Overlap Syndromes) is an international European-American cooperation providing the framework for collaborative studies to advance treatment of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and explore clinical-pathologic markers of disease severity, prognosis and treatment response. ABNL MARRO 001 (AM-001) is an Open label, phase 1/2 study within the framework of the ABNL-MARRO that will test novel treatment combinations in MDS/MPN. Each Arm of AM-001 will test an active myeloid target compound in combination with ASTX727, an oral drug combining fixed doses of the DNA methyltransferase inhibitor (DNMTi) decitabine and the cytidine deaminase inhibitor E7727, also known as cedazuridine in a single tablet. Type: Interventional Start Date: Dec 2021 |
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection
Hemolytic-Uremic Syndrome
The objective of this study is to determine if early high volume intravenous fluid
administration (hyperhydration) may be effective in mitigating or preventing
complications of shiga toxin-producing E. coli (STEC) infection in children and
adolescents when compared with traditional approaches (conservative... expand
The objective of this study is to determine if early high volume intravenous fluid administration (hyperhydration) may be effective in mitigating or preventing complications of shiga toxin-producing E. coli (STEC) infection in children and adolescents when compared with traditional approaches (conservative fluid management). Type: Interventional Start Date: Sep 2022 |
Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry
Pulmonary Vascular Disease
Pulmonary Arterial Hypertension
Patients are being asked to be in this research study because medical researchers hope
that by gathering information about a large number of children with pulmonary
hypertension over time, their understanding of the disease process will increase and lead
to better treatment. Investigators believe... expand
Patients are being asked to be in this research study because medical researchers hope that by gathering information about a large number of children with pulmonary hypertension over time, their understanding of the disease process will increase and lead to better treatment. Investigators believe that pulmonary hypertension in children is different than pulmonary hypertension in adults and this study will help us understand those differences. Type: Observational [Patient Registry] Start Date: Oct 2014 |
Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Familial Pulmonary Fibrosis
Idiopathic Interstitial Pneumonia
Familial Interstitial Pneumonia
The purpose of this study is to investigate inherited genetic factors that play a role in
the development of familial pulmonary fibrosis and to identify a group of genes that
predispose individuals to develop pulmonary fibrosis. Finding the genes that cause
pulmonary fibrosis is the first step at... expand
The purpose of this study is to investigate inherited genetic factors that play a role in the development of familial pulmonary fibrosis and to identify a group of genes that predispose individuals to develop pulmonary fibrosis. Finding the genes that cause pulmonary fibrosis is the first step at developing better methods for early diagnosis and improved treatment for pulmonary fibrosis. The overall hypothesis is that inherited genetic factors predispose individuals to develop pulmonary fibrosis. Type: Observational Start Date: Jul 2008 |
- Previous
- Next